Edition:
India

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

4.17USD
15 Dec 2017
Change (% chg)

$0.04 (+0.97%)
Prev Close
$4.13
Open
$4.13
Day's High
$4.24
Day's Low
$3.92
Volume
82,572
Avg. Vol
96,690
52-wk High
$22.16
52-wk Low
$3.21

Chart for

About

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal... (more)

Overall

Beta: -8.40
Market Cap(Mil.): $71.13
Shares Outstanding(Mil.): 0.12
Dividend: --
Yield (%): --

Financials

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

09 Dec 2017

BRIEF-Akari Therapeutics proposes public offering of ADS

* Akari Therapeutics announces proposed public offering of American Depositary Shares Source text for Eikon: Further company coverage:

18 Oct 2017

BRIEF-Akari Therapeutics announces further clinical progress

* Akari Therapeutics - 3 additional patients have been enrolled in ongoing Phase II Cobalt clinical trial of Coversin in patients with PNH​

11 Oct 2017

BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

* ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

21 Sep 2017

BRIEF-Akari Therapeutics appoints David Horn Solomon as CEO

* Akari Therapeutics announces appointment of David Horn Solomon as CEO

21 Aug 2017

BRIEF-Akari Therapeutics PLC files for mixed shelf of up to $100 mln

* Akari Therapeutics PLC files for mixed shelf of up to $100 million – SEC filing Source text: (http://bit.ly/2vLqRqG) Further company coverage:

19 Aug 2017

Earnings vs. Estimates